Author:
Wesolowski Robert,Peereboom David,Weiss Patricia,Elson Paul,Thomas Budd George
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference19 articles.
1. De Laurentiis M, Cancello G, D'Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53. doi: 10.1200/JCO.2007.11.3787
2. Ellis G, Livingstron RB (1993) Feasibility of dose-intensive continuous 5-FU, doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer. Cancer 71:392–396. doi: 10.1002/1097-0142(19930115)71:2<392::AID-CNCR2820710220>3.0.CO;2-Y
3. Ellis GK, Livingston RB (1994) Augmented dose intensity with concurrent G-CSF and continuous 5-FU. Adriamycin and cyclophosphamide chemotherapy for breast cancer. Proc ASCO. 13:53
4. Ellis GK, Green S, Livingston RB et al (1999) 'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study. Am J Clin Oncol 22(5):446–449. doi: 10.1097/00000421-199910000-00004
5. Ellis GK, Green SJ, Russell CA et al (2006) SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol, 2006 Proceedings of ASCO 24(18S):LBA537
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献